The Einstein/MMC CFAR Virology Core provides essential and highly used services to CFAR investigators that supply the infrastructure, resources, assays and techniques that permit Einstein/MMC CFAR basic and clinical investigators to investigate different aspects of HIV-1 replication in vitro and in vivo. This greatly facilitates their research efforts by allowing them to quickly and efficiently perform experiments that they could not otherwise do. For investigators who have experience in handling HIV-1, the BSLS/Virology core provides a dedicated BSL3 facility that contains the essential equipment for culturing HIV-1 under the appropriate biosafety conditions. For investigators whose research program requires them to culture HIV-1 but who do not have experience culturing HIV-1, the BSL3/Virology Core trains them in the various techniques and protocols required to safely handle and reliably culture HIV-1. Regular workshops are presented to teach investigators techniques for the measurement of p24 antigen by ELISA, co-culture of HIV-1 from PBMCs, performance of HIV-1 fusion assays using luciferase reporter pseudotyped HIV-1, measurement of plasma HIV-1 RNA levels, and determining viral titers using reporter cell lines. For clinical investigators, the core provides up-to-date, clinically relevant virological assays such as the quantification of plasma HIV-1 RNA and HCV RNA, isolation and phenotypic analysis of HIV, and isolation and storage of PBMC, plasma and/or serum from study patients. The Core also provides support for a wide range of molecular biology techniques including custom vector and plasmid design and construction, DNA sub-cloning and amplification, site-directed mutagenesis, large-scale expression of recombinant HIV, human or other pathogen proteins, siRNA interference construct design, and the heteroduplex mobility assay.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine
United States
Zip Code
Lankowski, Alexander J; Bien-Gund, Cedric H; Patel, Viraj V et al. (2018) PrEP in the Real World: Predictors of 6-Month Retention in a Diverse Urban Cohort. AIDS Behav :
Kirichenko, Tatiana V; Myasoedova, Veronika A; Shimonova, Tatiana E et al. (2018) Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Biosci Rep 38:
Auld, Sara C; Shah, N Sarita; Mathema, Barun et al. (2018) Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. Eur Respir J 52:
Harbut, Michael B; Yang, Baiyuan; Liu, Renhe et al. (2018) Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. Angew Chem Int Ed Engl 57:3478-3482
Patel, Viraj V; Dange, Alpana; Rawat, Shruta et al. (2018) Barriers to HIV Testing Among Men Who Have Sex With Men in India Reached Online: Implications for Interventions. J Acquir Immune Defic Syndr 78:e30-e34
Vilchèze, Catherine; Kim, John; Jacobs Jr, William R (2018) Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Antimicrob Agents Chemother 62:
Patel, Viraj V; Ginsburg, Zoë; Golub, Sarit A et al. (2018) Empowering With PrEP (E-PrEP), a Peer-Led Social Media-Based Intervention to Facilitate HIV Preexposure Prophylaxis Adoption Among Young Black and Latinx Gay and Bisexual Men: Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc 7:e11375
Megra, Bezawit W; Eugenin, Eliseo A; Berman, Joan W (2017) The Role of Shed PrPc in the Neuropathogenesis of HIV Infection. J Immunol 199:224-232
Usyk, Mykhaylo; Zolnik, Christine P; Patel, Hitesh et al. (2017) Novel ITS1 Fungal Primers for Characterization of the Mycobiome. mSphere 2:
Fox, Aaron D; Sohler, Nancy L; Frost, Taeko et al. (2017) Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduct J 14:23

Showing the most recent 10 out of 531 publications